Janssen-Cilag Ltd.
A Real-world Study in Participants With Smoldering Multiple Myeloma
- Conditions
- Smoldering Multiple Myeloma
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT06472778
- Locations
- 🇬🇧
Barts Hospital, London, United Kingdom
🇫🇷CHU Montpellier, Montpellier, France
🇮🇹Azienda Ospedaliera Universitaria Policlinico Umberto I - Universita di Roma La Sapienza, Roma, Italy
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 112
- Registration Number
- NCT06408935
- Locations
- 🇪🇸
Hosp. Gral. Univ. Dr. Balmis, Alicante, Spain
🇪🇸Hosp Reina Sofia, Cordoba, Spain
🇪🇸Complejo Hosp Univ. de Ferrol, Ferrol, Spain
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
- Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Interventions
- Other: TeclistamabOther: Talquetamab
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 600
- Registration Number
- NCT06285318
- Locations
- 🇫🇷
Hopital Saint Louis, Paris, France
🇸🇪Karolinska Universitetssjukhuset, Stockholms, Sweden
🇸🇪Uddevalla Hospital, Uddevalla, Sweden
A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT05901649
- Locations
- 🇦🇹
Klinikum Wels Grieskirchen, Wels, Austria
🇦🇹Akh Wien, Wien, Austria
🇫🇷Institut Sainte Catherine, Avignon, France
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
- Conditions
- Fistulizing Crohns DiseasePerianal Crohns Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 280
- Registration Number
- NCT05347095
- Locations
- 🇧🇪
Hopital Erasme, Bruxelles, Belgium
🇧🇪UZ Leuven, Leuven, Belgium
🇧🇪CHU Sart Tilman, Liege, Belgium
Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2021-11-18
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT05125679
- Locations
- 🇩🇪
Universitatsklinikum Leipzig AOR, Leipzig, Germany
🇩🇪Universitatsklinikum Frankfurt, Frankfurt, Germany
🇬🇷Attikon Hospital, Athens, Greece
A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 183
- Registration Number
- NCT04829318
- Locations
- 🇵🇱
Osrodek Badan Klinicznych CLINSANTE S C, Torun, Poland
🇵🇱Centrum Badan Klinicznych PI House sp z o o, Gdansk, Poland
🇦🇷FunDaMos, Ciudad Autonoma de Buenos Aires, Argentina
A Study of Participants With Moderate or Severe Major Depressive Disorder (MDD) Requiring Urgent Symptom Control in a Psychiatric Emergency
- Conditions
- Depressive Disorder, Major
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 220
- Registration Number
- NCT04829669
- Locations
- 🇬🇧
Greater Manchester Mental Health NHSFT, Manchester, United Kingdom
🇬🇧Greater Manchester Mental Health NHSFT, Manchester, United Kingdom
A Study to Evaluate the Impact of Care4Today® IBD, a Smart System to Facilitate the Management of Crohn's Disease by Patients and Health Care Providers
- Conditions
- Crohn Disease
- Interventions
- Other: No intervention
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT04232228
- Locations
- 🇬🇧
Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment
- Conditions
- Multiple Myeloma
- Interventions
- Other: No intervention
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 254
- Registration Number
- NCT04035226
- Locations
- 🇫🇷
Centre Hospitalier Régional Universitaire de Lille, Hôpital Claude Huriez, Lille Cedex, France
🇫🇷C.H.U. Hotel Dieu - France, Nantes, France
🇫🇷Hopital Saint-Antoine, PARIS cedex 12, France